Charles River Laboratories International, Inc. (CRL)
| Previous Close | 233.47 |
| Open | 235.60 |
| Bid | 234.32 x 900 |
| Ask | 234.48 x 800 |
| Day's Range | 233.28 - 235.84 |
| 52 Week Range | 161.65 - 275.00 |
| Volume | |
| Avg. Volume | 540,520 |
| Market Cap | 12.059B |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | 25.39 |
| EPS (TTM) | 9.22 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 270.80 |
ZacksCharles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
ZacksSotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates
Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireCharles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
WILMINGTON, Mass., May 02, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
